Kaplan‐Meier survival analysis further revealed that higher CCL5 expression was associated with poorer OS and PFS in patients with GC (Figure 7F), suggesting that CCL5 not only contributes to GC progression but also serves as a prognostic marker. The gene discussed is CCL5; the disease is gastric cancer.